Ying Buechler
Chief Tech/Sci/R&D Officer at AMBRX INC
Profile
Ying J.
Buechler is currently the Chief Technology Officer at Ambrx, Inc. Prior to this role, Buechler held positions at aTyr Pharma, Inc. as the Director-Protein Services, at Egen, Inc. as the Vice President-Development, at Canji, Inc. as a Scientist, and at Prizm Pharmaceuticals, Inc. as a Principal.
Buechler completed their undergraduate degree at Peking University and their doctorate degree at the University of California San Diego.
Ying Buechler active positions
| Companies | Position | Start |
|---|---|---|
| AMBRX INC | Chief Tech/Sci/R&D Officer | 2022-09-30 |
Former positions of Ying Buechler
| Companies | Position | End |
|---|---|---|
Canji, Inc.
 Canji, Inc. Medical/Nursing ServicesHealth Services Part of Merck & Co., Inc., Canji, Inc. is a gene therapy research company. The private company is based in San Diego, CA. Canji was acquired by Schering-Plough Corp., part of Merck & Co., Inc. from November 03, 2009 on February 02, 1996 for $54.50 million. | Corporate Officer/Principal | - |
Egen, Inc.
 Egen, Inc. Medical SpecialtiesHealth Technology Egen, Inc. operates as a clinical stage biopharmaceutical company which develops novel proprietary nanoparticle delivery technology for therapeutic use. Egen's technology platform is very broad, including polymer, cationic lipid, and molecular biology-based approaches to delivery of nucleic acid and anti-cancer drugs. The primary activities of the company are the application of the TheraPlas and TheraSilence platforms to the treatment of human disease. Egen's lead candidate, EGEN-001, is in Phase II clinical testing for ovarian cancer and in Phase I clinical testing for colorectal cancer. In addition, Egen is pursuing pre-clinical development of its TheraSilence RNAi delivery program for multiple disease applications, as well as other novel disruptive technologies focused on creating the next generation of synthetic nanoparticle delivery systems and nucleic acid-based therapies. It is also active in pursuing partnerships and working with external collaborators to further develop its delivery technology for multiple applications. Egen offers cutting-edge research services relating to non-viral polymeric gene carrier systems, and other approaches for the delivery of nucleic acid and anti-cancer drugs. The company's synthetic biocompatible delivery vehicles can be used to deliver therapeutic genes, inhibitory RNA (RNAi), and small molecules by protecting the therapeutic cargo from degradation, promoting uptake by target cells, and facilitating intracellular trafficking. Egen was founded in 2002 by Sung Wan Kim and is headquartered in Huntsville, AL. | Corporate Officer/Principal | - |
| Prizm Pharmaceuticals, Inc. | Corporate Officer/Principal | - |
| ATYR PHARMA, INC. | Corporate Officer/Principal | - |
Training of Ying Buechler
| Peking University | Undergraduate Degree |
| University of California San Diego | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ATYR PHARMA, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Egen, Inc.
Egen, Inc. Medical SpecialtiesHealth Technology Egen, Inc. operates as a clinical stage biopharmaceutical company which develops novel proprietary nanoparticle delivery technology for therapeutic use. Egen's technology platform is very broad, including polymer, cationic lipid, and molecular biology-based approaches to delivery of nucleic acid and anti-cancer drugs. The primary activities of the company are the application of the TheraPlas and TheraSilence platforms to the treatment of human disease. Egen's lead candidate, EGEN-001, is in Phase II clinical testing for ovarian cancer and in Phase I clinical testing for colorectal cancer. In addition, Egen is pursuing pre-clinical development of its TheraSilence RNAi delivery program for multiple disease applications, as well as other novel disruptive technologies focused on creating the next generation of synthetic nanoparticle delivery systems and nucleic acid-based therapies. It is also active in pursuing partnerships and working with external collaborators to further develop its delivery technology for multiple applications. Egen offers cutting-edge research services relating to non-viral polymeric gene carrier systems, and other approaches for the delivery of nucleic acid and anti-cancer drugs. The company's synthetic biocompatible delivery vehicles can be used to deliver therapeutic genes, inhibitory RNA (RNAi), and small molecules by protecting the therapeutic cargo from degradation, promoting uptake by target cells, and facilitating intracellular trafficking. Egen was founded in 2002 by Sung Wan Kim and is headquartered in Huntsville, AL. | Health Technology |
Canji, Inc.
Canji, Inc. Medical/Nursing ServicesHealth Services Part of Merck & Co., Inc., Canji, Inc. is a gene therapy research company. The private company is based in San Diego, CA. Canji was acquired by Schering-Plough Corp., part of Merck & Co., Inc. from November 03, 2009 on February 02, 1996 for $54.50 million. | Health Services |
| Prizm Pharmaceuticals, Inc. | Health Technology |
Ambrx, Inc.
 Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
- Stock Market
- Insiders
- Ying Buechler